Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?

Vincenzo Serretta, Cristina Scalici Gesolfo, Vincenza Alonge, Giuseppe Cicero, Marco Moschini, Renzo Colombo

Research output: Contribution to journalArticle

Abstract

Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.

Original languageEnglish
Pages (from-to)20-24
Number of pages5
JournalUrologia Internationalis
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Quality of Life
Recurrence

Keywords

  • Bacillus Calmette Guèrin
  • Compliance
  • Immunotherapy
  • Intravesical instillation
  • Non-muscle invasive bladder cancer
  • Toxicity

ASJC Scopus subject areas

  • Urology

Cite this

Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? / Serretta, Vincenzo; Gesolfo, Cristina Scalici; Alonge, Vincenza; Cicero, Giuseppe; Moschini, Marco; Colombo, Renzo.

In: Urologia Internationalis, Vol. 96, No. 1, 01.01.2016, p. 20-24.

Research output: Contribution to journalArticle

Serretta, Vincenzo ; Gesolfo, Cristina Scalici ; Alonge, Vincenza ; Cicero, Giuseppe ; Moschini, Marco ; Colombo, Renzo. / Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?. In: Urologia Internationalis. 2016 ; Vol. 96, No. 1. pp. 20-24.
@article{98e3fa0cdfab4897841518e1bff45100,
title = "Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?",
abstract = "Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50{\%} of patients don't complete it. Toxicity accounts for 10{\%} of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5{\%}) completed the induction cycle and 215 (52.3{\%}) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1{\%}) and 60 (14.6{\%}) patients. Ninetythree patients (30.2{\%}) stopped BCG, 9 (9.7{\%}) for recurrence and 14 (15.1{\%}) for grade-3 toxicity. Intriguingly, 55 (59.1{\%}) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60{\%} of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.",
keywords = "Bacillus Calmette Gu{\`e}rin, Compliance, Immunotherapy, Intravesical instillation, Non-muscle invasive bladder cancer, Toxicity",
author = "Vincenzo Serretta and Gesolfo, {Cristina Scalici} and Vincenza Alonge and Giuseppe Cicero and Marco Moschini and Renzo Colombo",
year = "2016",
month = "1",
day = "1",
doi = "10.1159/000430501",
language = "English",
volume = "96",
pages = "20--24",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?

AU - Serretta, Vincenzo

AU - Gesolfo, Cristina Scalici

AU - Alonge, Vincenza

AU - Cicero, Giuseppe

AU - Moschini, Marco

AU - Colombo, Renzo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.

AB - Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.

KW - Bacillus Calmette Guèrin

KW - Compliance

KW - Immunotherapy

KW - Intravesical instillation

KW - Non-muscle invasive bladder cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84956839074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956839074&partnerID=8YFLogxK

U2 - 10.1159/000430501

DO - 10.1159/000430501

M3 - Article

AN - SCOPUS:84956839074

VL - 96

SP - 20

EP - 24

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -